奥沙利铂联合长春瑞滨治疗晚期非小细胞肺癌临床疗效观察

Clinical Study on Oxaliplatin Plus Vinorelbine in Advanced Non- Small- Cell lung Cancer

目的价奥沙利铂联合长春瑞滨治疗晚期非小细胞肺癌的疗效和不良反应。方法化疗方案:长春瑞滨25mg/m2静脉滴注第1、8天,奥沙利铂130mg/m2静脉滴注第2天,3周重复。治疗2个周期后评价疗效。结果全组28例,CR1例(3.5%),PR9例(32.1%),NC8例(28.6%),PD10例(35.7%),总有效率(CR+PR)35.7%;中位生存期8.4个月;中位缓解期4.8个月;1年生存率为38.9%。不良反应以骨髓抑制、静脉炎及消化道反应为主。结论沙利铂联合长春瑞滨治疗晚期非小细胞肺癌疗效确切,不良反应轻,值得临床进一步研究。

Objective To study the efficiency and toxicity of oxaliplatin plus vinorebine chemtherapy in treatment of advanced non-small-cell lung cancer. Methods Vinorelbine was administered on days 1 and 8, with dose of 25 mg/m^2. Oxaliplatin was given at the dose of 130 mg/m^2 on day 2. Treatment was repeated every 3 weeks. The effect was evaluated after 2 cycles. Results There were twenty-eight patients. There were 1 complete responses （3.5 %）, 9 partial responses （32.1 %）, 8 stable diseases （28.6 %）, 10 progressive diseases（35.7 %）. The response rate was 35.7 %. The median overall survival time was 8.4 months, the median duration of response was 4.8 months and 1-year survival rate was 38.9 %. The major toxicities were myelosuppression, nausea/vomiting, phlebitis. Conclusion The oxaliplatin-vinorelbine combined chemotherapy is an active regimen for adcanced non-small-cell lung cancer with tolerable toxicity and deserves further evaluation.